This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemiplimab.

NIAID Data Ecosystem10

Transcriptomic Profiling of Peripheral Immune Cells in a Trial of Ruxolitinib with Nivolumab for PD1 non-responsive cHL

肿瘤免疫治疗

霍奇金淋巴瘤转录组

Treatment with checkpoint inhibitors is effective in multiple cancer types. However, even in cancers with high response rates such as Hodgkin lymphoma, some patients fail to respond or relapse followi

NIAID Data Ecosystem00

Genetically engineered superantigens as tolerable antitumor agents

肿瘤免疫治疗

超抗原工程

Superantigens (SAg) are a family of bacterial and viral proteins with strong immunostimulatory properties. SAg bound to major histocompatibility complex (MHC) class II molecules activate a high freque

PubMed Central1997-03-18 更新10

DataSheet4_A systematic pan-cancer analysis reveals the clinical prognosis and immunotherapy value of C-X3-C motif ligand 1 (CX3CL1).ZIP

癌症生物标志物

肿瘤免疫治疗

It is now widely known that C-X3-C motif ligand 1 (CX3CL1) plays an essential part in the process of regulating pro-inflammatory cells migration across a wide range of inflammatory disorders, includin

NIAID Data Ecosystem00